FDA
Lilly Strikes $11.5B in Three Deals as Regeneron Clears Otarmeni
Eli Lilly struck deals worth up to $11.55 billion across three acquisitions in two weeks: an up-to-$2.25 billion pact with AI biotech Profluent for genetic…
Latest — Page 11
Legal
Canada Moves to Ban Crypto ATMs After $704M Fraud Year
Canada's 2026 Spring Economic Update, released Tuesday, proposes banning crypto ATMs nationwide.
FDA
Posted $15.3B Q1, AstraZeneca Backs $80B 2030 Revenue Target
AstraZeneca posted $15.3 billion in first-quarter sales, led by Enhertu and Imfinzi, clearing the $14.7 billion analyst consensus and reinforcing CEO Pascal…
Deals
Paid $1.9B: Chiesi Bought KalVista and Its Approved Drug
Chiesi paid roughly $1.9 billion to buy KalVista Pharmaceuticals, an Italian pharma adding a commercial-stage biotech to its portfolio.
Legal
Arrested in Patagonia, Stericycle Finance Chief Faces June 1 FCPA Trial
DOJ charged Abraham Cigarroa Cervantes, former finance director of Stericycle's Latin America division, with two counts of conspiracy under the Foreign…
FDA
FDA Debuts Real-Time Clinical Trial Data Pilot
FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers direct access to trial results as they…
Legal
ShinyHunters Hits Udemy with 1.4M-Record Extortion Demand
ShinyHunters claims it breached Udemy, one of the world's largest online learning platforms, and is threatening to publish 1.4 million customer and…
Legal
Breached via Anodot, Vimeo Faces ShinyHunters' April 30 Ultimatum
ShinyHunters, the extortion group behind a wave of Snowflake-linked breaches, has put Vimeo on a clock: pay up or face a public data dump by April 30.
Deals
AbbVie Buys $1.45B Option on Kestrel's KRAS Program
AbbVie has secured an exclusive right to buy Kestrel Therapeutics for up to $1.45 billion, with the biotech required to hit unspecified development and…
FDA
Boehringer-Zealand Obesity Drug Posts 13.4%, Trails Zepbound
Survodutide posted 13.4% placebo-controlled weight loss at 76 weeks in the SYNCHRONIZE-1 Phase 3 trial, solid enough to clear both primary endpoints, but…
FDA
Cleared 2 Phase 3 Trials, Incyte Plans Povorcitinib Vitiligo Filing
Incyte will file for FDA approval of povorcitinib, its oral JAK1 inhibitor pill, in nonsegmental vitiligo after the drug hit in both of its Phase 3 trials.
FDA
FDA Moves to Strip Amgen's $459M Tavneos Over Manipulated Data
FDA proposed to rescind the approval of Tavneos, Amgen's oral treatment for ANCA-associated vasculitis, after CDER concluded that data from the drug's…
Legal
Charged: Scattered Spider's 'Bouquet,' 19, Faces 6 Federal Counts
Federal prosecutors charged a 19-year-old dual U.S.-Estonian citizen with wire fraud, conspiracy, and computer intrusion, alleging he's a prolific member of…
FDA
Passed Phase 3: Rezzayo Puts CorMedix's $300M Melinta Buy to Work
Rezzayo passed phase 3.
Deals
Sun Pharma Bought Organon for $11.75B, Debt Included
Sun Pharma paid $11.75 billion, or $14 a share in cash, to buy Organon in a deal that positions the India-based generics maker among the world's biosimilar…
